Skip to main content
< Back to news
David Resina, CEO of Bioingenium.
 28.10.2016

CZ Veterinaria and Bioingenium collaborate in the development of new vaccines

Bioingenium, a biotech service company based at the Barcelona Science Park (PCB), and the Galician biopharmaceutical company CZ Veterinaria announce their collaboration in the development of new generation vaccines. CZ Veterinary will invest in a new project where Bioingenium technology is used for the production of recombinant vaccines of new generation, able to improve the protection of animals against diseases. The project started in 2016 and now this new vaccine has successfully passed the first tests in experimental stages.

 

The production technology allows Bioingenium ‘s vaccines to advance in the field of veterinary medicine by reducing or eliminating the disadvantages of conventional vaccines production and improving their safety and effectiveness.

Bioingenium is a biotechnology services company located in the Barcelona Science Park that carries out its work since 2008. Bioingenium develops vaccines, therapeutic proteins and antigens for diagnostic, pharmaceutical and veterinary industry.

CZ Veterinaria is dedicated exclusively to the development and manufacture of vaccines and medicines for animal health. CZV has its own products which are distributed by third party companies and also manufactures a wide range of biological and pharmacological products for multinationals and governments around the world with presence in over 65 countries.